From: Human antibody response to dengue virus: implications for dengue vaccine design
Infecting serotype (n)a | Number of Patients | DENV neutralizing antibody titer (PRNT50) | |||||||
---|---|---|---|---|---|---|---|---|---|
BHK cells | FcγR-expressing BHK cells | ||||||||
DENV-1 | DENV-2 | DENV-3 | DENV-4 | DENV-1 | DENV-2 | DENV-3 | DENV-4 | ||
DENV-1 (7) | 3b | 10–80 | 10–1280 | <10–20 | <10–20 | <10 | <10–160 | <10 | <10 |
4 | <10 | 10–320 | <10 | <10 | <10 | <10–40 | <10 | <10 | |
DENV-3 (10) | 8b | 10–80 | <10–1280 | 10–40 | <10–40 | <10–20 | <10–80 | <10 | <10 |
2 | <10 | 80–160 | <10 | <10 | <10 | 20–40 | <10 | <10 |